Esperion Therapeutics ESPR Other accrued liabilities
Other accrued liabilities at other companies
Other financials
Where this comes from
Reported directly by Esperion Therapeutics in its filing.
Tagged under the XBRL concept espr:AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent.
The official record: Esperion Therapeutics’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Esperion Therapeutics's other accrued liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Esperion Therapeutics's other accrued liabilities?
- Esperion Therapeutics (ESPR) reported other accrued liabilities of $17.49M in Q1 2026.
- How has Esperion Therapeutics's other accrued liabilities changed year-over-year?
- Esperion Therapeutics's other accrued liabilities increased by 5.2% year-over-year, from $16.63M to $17.49M.
- What is the long-term trend for Esperion Therapeutics's other accrued liabilities?
- Over 5 years (2020 to 2025), Esperion Therapeutics's other accrued liabilities has grown at a -4.9% compound annual growth rate (CAGR), from $24.79M to $19.25M.
- What does other accrued liabilities mean?
- This encompasses various short-term obligations including employee-related costs such as bonuses, benefits, and payroll taxes, as well as general operating expenses. It serves as a proxy for the company's immediate administrative and operational overhead. Consistent monitoring helps assess the company's ability to manage its short-term working capital requirements.